

1<sup>st</sup> Translational Research E-Conference: Chronic Lymphocytic Leukaemia  
November 16-19, 2020  
Chairs: Jennifer Brown (Boston), Paolo Ghia (Milan), Michael Hallek (Cologne)

*This program is presented according to Central European Time (CET).  
Please check the corresponding hours in your time zone.*

**Monday, November 16, 2020**

13:50-14:00 Welcome

**SESSION I – The genomic and epigenomic landscape of CLL and clinical consequences**  
**Chairs: Jennifer Brown (Boston), Christopher Oakes (Columbus)**

14:00-14:05	Introduction	Jennifer Brown (Boston) Christopher Oakes (Columbus)
14:05-14:20	Genetic predisposition	Jennifer Brown (Boston)
14:20-14:35	Genetic landscape	Cathy Wu (Boston)
14:35-14:50	Ibrutinib resistance	Jennifer Woyach (Columbus)
14:50-15:05	Epigenetic landscape	Christopher Oakes (Columbus)
15:05-15:20	Risk stratification in CLL	Antonio Cuneo (Ferrara)
15:20-15:50	<i>General Discussion</i>	

**SESSION II – The role of BCR activation and signalling for CLL**  
**Chairs: Paolo Ghia (Milan), Kostas Stamatopoulos (Thessaloniki)**

15:50-15:55	Introduction	Paolo Ghia (Milan) Kostas Stamatopoulos (Thessaloniki)
15:55-16:10	BCR isotypes/autonomous signalling	Hassan Jumaa (Ulm)
16:10-16:25	The latest news on stereotypes	Kostas Stamatopoulos (Thessaloniki)
16:25-16:40	Novel BCR targets	Andrew Steele (Southampton)
16:40-16:55	Next generation BTK inhibitors (covalent/non-covalent?)	Anthony Mato (New York)

**SHORT ORAL COMMUNICATION**

16:55-17:02	<i>Mutational landscape of CLL mice models overexpressing aid identify proliferative-associated tumor genes involved in leukemic progression</i>	Pablo Oppezzo (Montevideo)
17:02- 17:32	<i>General discussion</i>	

**17:35-18:35 Clinical Poster Walk**

**Leaders:** Matthew Davids (Boston), Alessandra Tedeschi (Milan)

18:35-20:30 *Dinner break. BUT do not forget to come back for....*

**SESSION III – Therapeutic options for CLL**

**Chairs:** Alain Delmer (Reims), Michael Hallek (Cologne)

20:30-20:35	Introduction	Alain Delmer (Reims) Michael Hallek (Cologne)
20:35-20:50	Ibrutinib for everybody	Jennifer Woyach (Columbus)
20:50-21:05	Ibrutinib for a small subgroup only	Florence Cymbalista (Bobigny)
21:05-21:20	MURANO and MRD	John Seymour (Melbourne)
21:20-21:35	CLL14 update	Kirsten Fischer (Cologne)

**SHORT ORAL COMMUNICATION**

21:35-21:42	<i>Neddylation pathway regulates treg differentiation and T-cell function in Chronic Lymphocytic Leukemia ex vivo and murine in vivo studies</i>	Scott Best (Portland)
21:42-22:12	<i>General Discussion</i>	

**Tuesday, November 17, 2020**

**13:00-14:00 Simultaneous Lunchtime Meet the Expert sessions**

1. Prognostic and predictive markers	Barbara Eichhorst (Cologne)/Loic Ysebaert (Toulouse)
2. First line therapy: continuous or time limited treatment?	Michael Hallek (Cologne)/Alessandra Tedeschi (Milan)

**SESSION IV – Long term follow up of clinical trials versus real world data (Outside Clinical Trials data-OCT)**

**Chair:** Jennifer Woyach (Columbus)

14:05-14:10	Introduction	Jennifer Woyach (Columbus)
14:10-14:25	Ibrutinib trials	Alessandra Tedeschi (Milan)
14:25-14:40	Ibrutinib real world	Loïc Ysebaert (Toulouse)
14:40-14:55	Venetoclax trials	Matthew Davids (Boston)
14:55-15:10	Venetoclax / PI3K real world	Lindsey Roeker (New York)

**SHORT ORAL COMMUNICATION**

15:10-15:17	<i>Sequential treatment with bendamustine, obinutuzumab (GA101) and ibrutinib in Chronic Lymphocytic Leukemia: final results of the CLL2-BIG trial of the German CLL study group (GCLLSG)</i>	Julia von Tresckow (Essen)
15:17-15:45	<i>General discussion</i>	

**15:50-16:50**

**SATELLITE SYMPOSIUM:**

**Utilization of MRD assessment in the clinical management of CLL patients**

**Chair: Barbara Eichhorst (Cologne)**

**Speakers: Barbara Eichhorst (Cologne), Lanny Kirsch (Seattle), Anna Schuh (Oxford)**

*This symposium is organised and funded by Adaptive Biotechnologies.*

**16:50-17:50 Meet the Expert session**

Resistance to ibrutinib: what to do

Jennifer Brown (Boston)/Anna Schuh (Oxford)

**16:50-17:50 Biology Poster Walk:**

**Leaders: Alexey Danilov (Duarte), Davide Rossi (Bellinzona)**

**Wednesday, November 18, 2020**

**SESSION V – The increasing role of the leukaemic microenvironment**

**Chairs: Silvia Deaglio (Turin), Adrian Wiestner (Bethesda)**

14:30-14:35 Introduction

Silvia Deaglio (Turin)  
Adrian Wiestner (Bethesda)

14:35-14:50 Role of stromal cells

Andrea Brendolan (Milan)

14:50-15:05 Hypoxia, metabolic reprogramming and immunosuppression occurring in CLL niche

Silvia Deaglio (Turin)

15:05-15:20 Role of T cells

Arnon Kater (Amsterdam)

15:20-15:35 Immunomodulatory effects of kinase inhibitors

Adrian Wiestner (Bethesda)

***SHORT ORAL COMMUNICATION***

15:35-15:42 *Expansion of antitumor cytotoxic CD8+ T cells in CLL patients treated with ibrutinib*

Maria Joao Baptista (Badalona)

15:42-16:12 *General discussion*

**SESSION VI – Therapeutic options 2: The use of cellular and non-cellular immunotherapies in CLL**

**Chairs: Matthew Davids (Boston), Peter Dreger (Heidelberg)**

16:15-16:20 Introduction

Matthew Davids (Boston)  
Peter Dreger (Heidelberg)

16:20-16:35 Next generation PI3K inhibitors

Peter Hillmen (Leeds)

16:35-16:50 Novel inhibitors at preclinical level (MCL1 & CDK inhibitors)

Alexey Danilov (Duarte)

16:50-17:05 Mechanistic effects of BH3 Mimetics in CLL

Eric Eldering (Amsterdam)

17:05-17:20	CAR-T cells	Stephen Schuster (Philadelphia)
17:20-17:35	Allo-transplant	Peter Dreger (Heidelberg)
17:35-18:05	<i>General discussion</i>	

### **SESSION VII – Efficacy through safety**

**Chairs: Barbara Eichhorst (Cologne), Javid Moslehi (Nashville)**

18:05-18:10	Introduction	Barbara Eichhorst (Cologne) Javid Moslehi (Nashville)
18:10-18:25	Cardiologist	Javid Moslehi (Nashville)
18:25-18:40	Dermatologist	Nicole LeBoeuf (Boston)
18:40-18:55	Infectious diseases	Michele Bartoletti (Bologna)
18:55-19:10	Gastroenterology	Stefano Fagioli (Bergamo)
19:10-19:40	<i>General discussion</i>	

Thursday, November 19, 2020

### **12:00-13:00 Simultaneous Lunchtime Meet the Expert sessions**

- |   |  |
|---|--|
| 1. Treatment of relapsed CLL                | Paolo Ghia (Milan)/Barbara Eichhorst (Cologne)     |
| 2. Management of novel drugs - side effects | Carol Moreno (Barcelona)/Davide Rossi (Bellinzona) |
| 3. MRD assessment                           | Andrew Rawstron (Leeds)/Arnon Kater (Amsterdam)    |

### **SESSION VIII – Clonal heterogeneity, clonal evolution and mechanisms of drug resistance**

**Chairs: Davide Rossi (Bellinzona), John Seymour (Melbourne)**

13:00-13:05	Introduction	Davide Rossi (Bellinzona) John Seymour (Melbourne)
13:05-13:20	Clonal evolution	Davide Rossi (Bellinzona)
13:20-13:35	PI3K	Jennifer Brown (Boston)
13:35-13:50	Venetoclax	John Seymour (Melbourne)

### **SHORT ORAL COMMUNICATIONS**

13:50-13:57	<i>Aid-mediated mechanisms of resistance to BCR inhibitors in Chronic Lymphocytic Leukemia (CLL)</i>	Chiara Pighi (Turin)
13:57-14:04	<i>NOTCH2 contributes to venetoclax resistance in Chronic Lymphocytic Leukemia</i>	Stefania Fiorcari (Modena)
14:04-14:35	<i>General discussion</i>	
14:35-14:45	<b>Coffee break</b>	

**SESSION IX – Contrasting therapeutic concepts**

**Chairs: Jennifer Brown (Boston), Michael Hallek (Cologne)**

14:45-14:50	Introduction	Jennifer Brown (Boston) Michael Hallek (Cologne)
14:50-15:05	MRD as a dynamic endpoint	Peter Hillmen (Leeds)
15:05-15:20	Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction in lymphoid malignancies including CLL	David M. Kurtz (Stanford)
15:20-15:35	Sequential vs combination treatments	William Wierda (Houston)
15:35-15:50	Time limited vs continuous treatments	Barbara Eichhorst (Cologne)
15:50-16:20	<i>General discussion</i>	
16:20-16:30	<i>Closing Remarks</i>	

**MEETING CLOSURE**